The pseudogene DUXAP10 promotes an aggressive phenotype through binding with LSD1 and repressing LATS2 and RRAD in non small cell lung cancer
Metrics: PDF 1874 views | HTML 2716 views | ?
Chen-Chen Wei1,*, Feng-Qi Nie1,*, Li-Li Jiang1,2,*, Qin-Nan Chen1, Zhen-Yao Chen1, Xin Chen1, Xuan Pan3, Zhi-Li Liu4, Bin-Bin Lu1, Zhao-Xia Wang1
1Department of Oncology, Second Affiliated Hospital, Nanjing Medical University, Nanjing, People’s Republic of China
2Department of Oncology, Haimen People’s Hospital, Haimen, People’s Republic of China
3Department of Medical Oncology, Nanjing Medical University Affiliated Cancer Hospital of Jiangsu Province, Cancer Institution of Jiangsu Province, Nanjing, People’s Republic of China
4Department of Oncology, The Affiliated Jiangyin Hospital, School of Medicine, Southeast University, Jiangyin, People’s Republic of China
*These authors contributed equally to this work and should be regarded as joint first authors
Zhao-Xia Wang, email: [email protected]
Keywords: pseudogene, DUXAP10, LSD1, proliferation, migration and invasion
Received: June 06, 2016 Accepted: November 21, 2016 Published: December 23, 2016
Pseudogenes have been considered as non-functional transcriptional relics of human genomic for long time. However, recent studies revealed that they play a plethora of roles in diverse physiological and pathological processes, especially in cancer, and many pseudogenes are transcribed into long noncoding RNAs and emerging as a novel class of lncRNAs. However, the biological roles and underlying mechanism of pseudogenes in the pathogenesis of non small cell lung cancer are still incompletely elucidated. This study identifies a putative oncogenic pseudogene DUXAP10 in NSCLC, which is located in 14q11.2 and 2398 nt in length. Firstly, we found that DUXAP10 was significantly up-regulated in 93 human NSCLC tissues and cell lines, and increased DUXAP10 was associated with patients poorer prognosis and short survival time. Furthermore, the loss and gain of functional studies including growth curves, migration, invasion assays and in vivo studies verify the oncogenic roles of DUXAP10 in NSCLC. Finally, the mechanistic experiments indicate that DUXAP10 could interact with Histone demethylase Lysine specific demethylase1 (LSD1) and repress tumor suppressors Large tumor suppressor 2 (LATS2) and Ras-related associated with diabetes (RRAD) transcription in NSCLC cells. Taken together, these findings demonstrate DUXAP10 exerts the oncogenic roles through binding with LSD1 and epigenetic silencing LATS2 and RRAD expression. Our investigation reveals the novel roles of pseudogene in NSCLC, which may serve as new target for NSCLC diagnosis and therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.